The GLP-1 "weight loss magic medicine" of the fire was finally approved in China. On July 4th, East China Pharmaceutical Co., Ltd. (East China Pharmaceutical, 000963) issued an announcement saying that Hangzhou China and the United States East China Pharmaceutical Co., Ltd. ("China -US East China") received the National Drug Administration (NMPA) for approval The "Pharmaceutical Registration Certificate" issued by East China, China, and the United States, is approved by the listing license application of obesity or overweight indication certificates declared by China and the United States.
Leralugin peptide is a human cordyl glucose-like peptide-1 (GLP-1) receptor agonist. It has 97%sequence homologous with human GLP-1 and is approved to improve adult type 2 diabetes (T2DM ) Blood glucose control and treatment of patients with obesity or overweight.